Managers / Q2 2019 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $288M in U.S.-listed holdings across 13 positions for Q2 2019.
Its largest position, QURE, represents 9.9% of the portfolio.
Compared with Q1 2019, the fund opened 2 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 53.1% · $153M
- Common Stock · 29.5% · $85M
- Other · 12.7% · $37M
- ADR · 4.7% · $13M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| BCYCBICYCLE THERAPEUTICS PLC | NEW | +737.5K | 737.5K | +$7M | $7M |
| PROQR THRAPEUTICS N V | NEW | +748.9K | 748.9K | +$7M | $7M |
| GALAPAGOS NV | ADDED | +25.0K | 46.8K | +$3M | $6M |
| IBBISHARES TR | ADDED | +500.0K | 1.00M | +$53M | $109M |
| PROQR THRAPEUTICS N V | SOLD OUT | −486.7K | 0 | −$7M | $0 |
| BLUEPRINT MEDICINES CORP | SOLD OUT | −30.6K | 0 | −$2M | $0 |
| CTMXCYTOMX THERAPEUTICS INC | SOLD OUT | −101.8K | 0 | −$1M | $0 |
| ARWRARROWHEAD PHARMACEUTICALS IN | TRIMMED | −425.0K | 557.5K | −$3M | $15M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | QUREUNIQURE NVhistory → | SHS | 9.89% | $28M | 364.6K |
| 2 | MERUS N V | COM | 7.08% | $20M | 1.39M |
| 3 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 5.13% | $15M | 557.5K |
| 4 | SPROSPERO THERAPEUTICS INChistory → | COM | 4.61% | $13M | 1.15M |
| 5 | FATEFATE THERAPEUTICS INChistory → | COM | 4.24% | $12M | 602.1K |
| 6 | SYNLOGIC INC | COM | 3.30% | $10M | 1.04M |
| 7 | XENEXENON PHARMACEUTICALS INChistory → | COM | 3.26% | $9M | 951.5K |
| 8 | BCYCBICYCLE THERAPEUTICS PLChistory → | SPONSORED ADS | 2.58% | $7M | 737.5K |
| 9 | PIERIS PHARMACEUTICALS INC | COM | 2.37% | $7M | 1.45M |
| 10 | PROQR THRAPEUTICS N V | SHS EURO | 2.37% | $7M | 748.9K |
| 11 | GALAPAGOS NV | SPON ADR | 2.10% | $6M | 46.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.